SAN DIEGO / Aug 05, 2025 / Business Wire / Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences:
Canaccord Genuity 45th Annual Growth Conference
Presenting on Wednesday, August 13, 2025, at 8:00 a.m. ET
Citi's 2025 Biopharma Back to School Conference
Presenting on Tuesday, September 2, 2025, at 3:15 p.m. ET
2025 Wells Fargo Healthcare Conference
Presenting on Wednesday, September 3, 2025, at 1:30 p.m. ET
Cantor Global Healthcare Conference 2025
Presenting on Thursday, September 4, 2025, at 2:45 p.m. ET
Live webcasts of the presentations will be accessible on the Investor page of Travere’s website at ir.travere.com/events-and-presentations. Replays will be available for up to 30 days following each event.
About Travere Therapeutics
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit www.travere.com.
| Last Trade: | US$36.26 |
| Daily Volume: | 0 |
| Market Cap: | US$3.240B |
October 30, 2025 October 17, 2025 September 10, 2025 September 03, 2025 | |

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load